Unknown

Dataset Information

0

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).


ABSTRACT: BACKGROUND:Symptom assessment requires psychometrically validated questionnaires that are easy to use, relevant to the disease, and quick to administer. The MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM) was adapted from the general (core) MDASI to assess the severity of cancer-related and treatment-related symptoms specific to patients with this condition. The MDASI-MPM includes the 13 core MDASI symptoms, which are experienced by most cancer patients, and 6 MPM-specific items developed via qualitative interviewing, a method favored by the US Food and Drug Administration for instrument item generation and development. Qualitative interviewing that summarizes the item generation and development for the MDASI-MPM is detailed in a separate report. The psychometric study reported here was the next step in developing the validation dossier for the MDASI-MPM. RESULTS:In this secondary analysis of data from a Phase II trial, 248 patients provided MDASI-MPM data at multiple timepoints during therapy. Over time, fatigue, pain, shortness of breath, feeling of malaise, and muscle weakness were consistently the worst symptoms reported; symptoms interfered most with work and general activity and least with relations with others. Cronbach coefficient alpha values for all MDASI-MPM subscales were at least 0.88 at baseline and 0.91 during treatment, indicating good internal consistency reliability. Intraclass correlations of at least 0.86 for all MDASI-MPM subscales administered a cycle apart (n?=?82) were indicative of good test-retest reliability. Correlations between MDASI-MPM subscales and LCSS-Meso scores were at least 0.70 (P?

SUBMITTER: Mendoza TR 

PROVIDER: S-EPMC6579804 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC3228083 | BioStudies
1000-01-01 | S-EPMC3598689 | BioStudies
2013-01-01 | S-EPMC3731927 | BioStudies
| S-EPMC4620084 | BioStudies
2019-01-01 | S-EPMC6708028 | BioStudies
2019-01-01 | S-EPMC6884899 | BioStudies
2019-01-01 | S-EPMC6367664 | BioStudies
1000-01-01 | S-EPMC3044634 | BioStudies
2011-01-01 | S-EPMC3075398 | BioStudies
2010-01-01 | S-EPMC2955020 | BioStudies